Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices

Sundar Jagannath; Anuja Roy; Jonathan Kish; Orsolya Lunacsek; Denise Globe; Michael Eaddy; Emil T. Kuriakose; Joanne Willey; Stephanie Butler-Bird; David Siegel

doi:10.1080/17474086.2016.1195254

Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices

Sundar Jagannath, Anuja Roy, Jonathan Kish, Orsolya Lunacsek, Denise Globe, Michael Eaddy, Emil T. Kuriakose, Joanne Willey, Stephanie Butler-Bird, David Siegel

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

Background: Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking. Methods: Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics. Results: Bortezomib ± a non-immunomodulatory drug (IMiD), lenalidomide ± a non-proteasome inhibitor (PI), bortezomib + an IMiD were the most commonly used regimens in early lines of therapy. Median PFS was similar in 1^st (11.1 months) and 2^nd line (10.5) and decreased in lines 3 through 5 (3^rd: 7.9; 4^th: 7.2, 5^th: 5.4). Longest PFS (12.5 months) in first line was with bortezomib + ImiD; longest PFS in second line was with lenalidomide ± a non-PI was (13.2 months). Conclusions: Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.

Original language	English
Pages (from-to)	707-717
Number of pages	11
Journal	Expert Review of Hematology
Volume	9
Issue number	7
DOIs	https://doi.org/10.1080/17474086.2016.1195254
State	Published - 2 Jul 2016
Externally published	Yes

Keywords

Duration of therapy
Multiple myeloma
Progression-free survival
Real-world evidence
Relapsed/refractory
Treatment patterns

Access to Document

10.1080/17474086.2016.1195254

Cite this

Jagannath, S., Roy, A., Kish, J., Lunacsek, O., Globe, D., Eaddy, M., Kuriakose, E. T., Willey, J., Butler-Bird, S., & Siegel, D. (2016). Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. Expert Review of Hematology, 9(7), 707-717. https://doi.org/10.1080/17474086.2016.1195254

@article{4fdaf338bacb4276a245980d06948dcf,

title = "Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices",

abstract = "Background: Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking. Methods: Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics. Results: Bortezomib ± a non-immunomodulatory drug (IMiD), lenalidomide ± a non-proteasome inhibitor (PI), bortezomib + an IMiD were the most commonly used regimens in early lines of therapy. Median PFS was similar in 1st (11.1 months) and 2nd line (10.5) and decreased in lines 3 through 5 (3rd: 7.9; 4th: 7.2, 5th: 5.4). Longest PFS (12.5 months) in first line was with bortezomib + ImiD; longest PFS in second line was with lenalidomide ± a non-PI was (13.2 months). Conclusions: Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.",

keywords = "Duration of therapy, Multiple myeloma, Progression-free survival, Real-world evidence, Relapsed/refractory, Treatment patterns",

author = "Sundar Jagannath and Anuja Roy and Jonathan Kish and Orsolya Lunacsek and Denise Globe and Michael Eaddy and Kuriakose, \{Emil T.\} and Joanne Willey and Stephanie Butler-Bird and David Siegel",

note = "Publisher Copyright: {\textcopyright} 2016 Informa UK Limited, trading as Taylor \& Francis Group.",

year = "2016",

month = jul,

day = "2",

doi = "10.1080/17474086.2016.1195254",

language = "English",

volume = "9",

pages = "707--717",

journal = "Expert Review of Hematology",

issn = "1747-4086",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

Jagannath, S, Roy, A, Kish, J, Lunacsek, O, Globe, D, Eaddy, M, Kuriakose, ET, Willey, J, Butler-Bird, S & Siegel, D 2016, 'Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices', Expert Review of Hematology, vol. 9, no. 7, pp. 707-717. https://doi.org/10.1080/17474086.2016.1195254

TY - JOUR

T1 - Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices

AU - Jagannath, Sundar

AU - Roy, Anuja

AU - Kish, Jonathan

AU - Lunacsek, Orsolya

AU - Globe, Denise

AU - Eaddy, Michael

AU - Kuriakose, Emil T.

AU - Willey, Joanne

AU - Butler-Bird, Stephanie

AU - Siegel, David

PY - 2016/7/2

Y1 - 2016/7/2

N2 - Background: Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking. Methods: Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics. Results: Bortezomib ± a non-immunomodulatory drug (IMiD), lenalidomide ± a non-proteasome inhibitor (PI), bortezomib + an IMiD were the most commonly used regimens in early lines of therapy. Median PFS was similar in 1st (11.1 months) and 2nd line (10.5) and decreased in lines 3 through 5 (3rd: 7.9; 4th: 7.2, 5th: 5.4). Longest PFS (12.5 months) in first line was with bortezomib + ImiD; longest PFS in second line was with lenalidomide ± a non-PI was (13.2 months). Conclusions: Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.

AB - Background: Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking. Methods: Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics. Results: Bortezomib ± a non-immunomodulatory drug (IMiD), lenalidomide ± a non-proteasome inhibitor (PI), bortezomib + an IMiD were the most commonly used regimens in early lines of therapy. Median PFS was similar in 1st (11.1 months) and 2nd line (10.5) and decreased in lines 3 through 5 (3rd: 7.9; 4th: 7.2, 5th: 5.4). Longest PFS (12.5 months) in first line was with bortezomib + ImiD; longest PFS in second line was with lenalidomide ± a non-PI was (13.2 months). Conclusions: Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.

KW - Duration of therapy

KW - Multiple myeloma

KW - Progression-free survival

KW - Real-world evidence

KW - Relapsed/refractory

KW - Treatment patterns

UR - https://www.scopus.com/pages/publications/84975113086

U2 - 10.1080/17474086.2016.1195254

DO - 10.1080/17474086.2016.1195254

M3 - Article

C2 - 27291638

AN - SCOPUS:84975113086

SN - 1747-4086

VL - 9

SP - 707

EP - 717

JO - Expert Review of Hematology

JF - Expert Review of Hematology

IS - 7

ER -

Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices

Abstract

Keywords

Access to Document

Fingerprint

Cite this